CA2478374C - N3 alkylated benzimidazole derivatives as mek inhibitors - Google Patents

N3 alkylated benzimidazole derivatives as mek inhibitors Download PDF

Info

Publication number
CA2478374C
CA2478374C CA002478374A CA2478374A CA2478374C CA 2478374 C CA2478374 C CA 2478374C CA 002478374 A CA002478374 A CA 002478374A CA 2478374 A CA2478374 A CA 2478374A CA 2478374 C CA2478374 C CA 2478374C
Authority
CA
Canada
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
nr3r4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002478374A
Other languages
English (en)
French (fr)
Other versions
CA2478374A1 (en
Inventor
Eli M. Wallace
Joseph P. Lyssikatos
T. Brian Hurley
Allison L. Marlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2478374(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CA2478374A1 publication Critical patent/CA2478374A1/en
Application granted granted Critical
Publication of CA2478374C publication Critical patent/CA2478374C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002478374A 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivatives as mek inhibitors Expired - Lifetime CA2478374C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36400702P 2002-03-13 2002-03-13
US60/364,007 2002-03-13
PCT/US2003/007864 WO2003077914A1 (en) 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivatives as mek inhibitors

Publications (2)

Publication Number Publication Date
CA2478374A1 CA2478374A1 (en) 2003-09-25
CA2478374C true CA2478374C (en) 2009-01-06

Family

ID=28041856

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478374A Expired - Lifetime CA2478374C (en) 2002-03-13 2003-03-13 N3 alkylated benzimidazole derivatives as mek inhibitors

Country Status (35)

Country Link
US (11) US20030232869A1 (OSRAM)
EP (5) EP2130536B1 (OSRAM)
JP (4) JP4093966B2 (OSRAM)
KR (3) KR100984595B1 (OSRAM)
CN (4) CN101486682B (OSRAM)
AR (3) AR038971A1 (OSRAM)
AT (1) ATE449605T1 (OSRAM)
AU (2) AU2003218157C1 (OSRAM)
BE (1) BE2019C510I2 (OSRAM)
BR (1) BR122018007328B8 (OSRAM)
CA (1) CA2478374C (OSRAM)
CL (2) CL2012002381A1 (OSRAM)
CY (3) CY1109727T1 (OSRAM)
DE (1) DE60330227D1 (OSRAM)
DK (4) DK3000810T3 (OSRAM)
DO (4) DOP2003000613A (OSRAM)
ES (5) ES2635666T3 (OSRAM)
FR (1) FR19C1014I2 (OSRAM)
HU (2) HUE025767T2 (OSRAM)
IL (4) IL163995A0 (OSRAM)
IS (4) IS2748B (OSRAM)
LT (1) LTC1482932I2 (OSRAM)
LU (1) LUC00100I2 (OSRAM)
MX (1) MXPA04008893A (OSRAM)
NL (1) NL300974I2 (OSRAM)
NZ (1) NZ535158A (OSRAM)
PA (1) PA8569301A1 (OSRAM)
PL (5) PL230179B1 (OSRAM)
PT (4) PT2130537E (OSRAM)
SG (3) SG2013013339A (OSRAM)
SI (4) SI2275102T1 (OSRAM)
TW (3) TWI350285B (OSRAM)
UA (1) UA77765C2 (OSRAM)
WO (1) WO2003077914A1 (OSRAM)
ZA (1) ZA200407220B (OSRAM)

Families Citing this family (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL230179B1 (pl) * 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003297925A1 (en) * 2002-12-13 2004-07-09 Smithkline Beecham Corporation Thrombopoietin mimetics
ES2324165T3 (es) * 2003-02-26 2009-07-31 Kowa Co., Ltd. Tratamiento de la dermatitis alergica de contacto.
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
TWI349664B (en) 2003-09-22 2011-10-01 S Bio Pte Ltd Benzimidazole derivatives: preparation and pharmaceutical applications
CN1905873A (zh) * 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
ZA200703912B (en) 2004-10-20 2008-09-25 Serono Lab 3-arylamino pyridine derivatives
ES2330872T3 (es) * 2004-12-01 2009-12-16 Merck Serono Sa Derivados de (1,2,4)triazolo(4,3-a)piridina para el tratamiento de enfermedades hiperproliferativas.
US7429667B2 (en) * 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
TW201238952A (en) * 2005-05-18 2012-10-01 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
AR054623A1 (es) * 2005-06-23 2007-07-04 Astrazeneca Ab PROCESO PARA PREPARAR DERIVADOS DE BENCIMIDAZOL Y COMPUESTOS INTERMEDIARIOS DE SíNTESIS DE LOS MISMOS.
WO2007002092A1 (en) * 2005-06-23 2007-01-04 Array Biopharma Inc. SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AU2013203939B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
EA032466B1 (ru) 2005-10-07 2019-05-31 Экселиксис, Инк. Способы получения ингибиторов mek
AU2012261703B2 (en) * 2005-10-07 2015-08-13 Exelixis, Inc. Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7572460B2 (en) * 2005-10-25 2009-08-11 Rodrigo Rodriguez-Kabana Hydrogen cyanamide pesticide formulations
US7968108B2 (en) * 2005-10-25 2011-06-28 Metbro Distributing L.P. Hydrogen cyanamide pesticide formulations
CN101341132A (zh) * 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
RU2418790C3 (ru) * 2005-12-21 2022-03-14 Астразенека Аб Новая гидросульфатная соль
CA2534243A1 (fr) 2006-01-25 2007-07-25 Hydro Quebec Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007121269A2 (en) 2006-04-11 2007-10-25 Ardea Biosciences, Inc. N-aryl-n'alkyl sulfamides as mek inhibitors
AU2007237901B2 (en) * 2006-04-18 2012-07-05 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
JP5268904B2 (ja) 2006-07-06 2013-08-21 アレイ バイオファーマ、インコーポレイテッド Ａｋｔプロテインキナーゼ阻害剤としてのシクロペンタ［ｄ］ピリミジン
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8492378B2 (en) * 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
ZA200901009B (en) * 2006-08-21 2010-05-26 Genentech Inc Aza-benzothiophenyl compounds and methods of use
MX2009001878A (es) * 2006-08-21 2009-03-03 Genentech Inc Compuestos de aza-benzofuranilo y metodos de uso.
AU2007286807B2 (en) * 2006-08-21 2013-03-21 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101678001A (zh) * 2007-04-13 2010-03-24 阿斯利康(瑞典)有限公司 包含azd2171和azd6244或mek-抑制剂ⅱ的组合治疗
US8509487B2 (en) * 2007-04-19 2013-08-13 Avago Technologies General Ip (Singapore) Pte. Ltd. System and method for optically measuring a parameter of an object
WO2008157179A2 (en) 2007-06-12 2008-12-24 Genentech, Inc. N-substituted azaindoles and methods of use
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AU2008272832B2 (en) * 2007-07-05 2014-02-20 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
BRPI0818426A2 (pt) * 2007-10-15 2017-06-13 Astrazeneca Ab produto de combinação, uso de um produto de combinação, e, método para tratar câncer
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
CL2008003810A1 (es) 2007-12-19 2009-05-22 Genentech Inc Compuestos derivados de 5-anilino imidazol[1,5-a]piridina o pirazina, inhibidores de la actividad mek quinasa; composiciones farmaceuticas que los contienen; y su uso para tratar trastornos hiperproliferativos y una enfermedad inflamatoria.
CN101903387B (zh) 2007-12-19 2014-05-21 健泰科生物技术公司 8-苯氨基咪唑并吡啶和它们在制备抗癌剂和/或抗炎剂中的用途
AU2008341680A1 (en) 2007-12-20 2009-07-02 F. Hoffmann-La Roche Ag Substituted hydantoins as MEK kinase inhibitors
EP2220092B1 (en) 2007-12-21 2012-06-06 Genentech, Inc. Azaindolizines and methods of use
CN101932564B (zh) * 2008-01-09 2012-12-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的羟基化嘧啶基环戊烷类
ES2401685T3 (es) * 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
WO2009093008A1 (en) 2008-01-21 2009-07-30 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
SA109300195B1 (ar) 2008-03-28 2013-04-20 Astrazeneca Ab تركيبة صيدلانية جديدة مضادة للسرطان
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8559963B2 (en) 2008-06-23 2013-10-15 Panasonic Corporation Wireless communication base station apparatus and reference signal allocation method
CN102137847B (zh) 2008-07-01 2015-06-10 健泰科生物技术公司 作为mek激酶抑制剂的二环杂环
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
SI2307376T1 (sl) 2008-08-04 2016-02-29 Merck Patent Gmbh Nove spojine fenilamino izonikotinamida
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120269803A1 (en) 2009-10-21 2012-10-25 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
WO2011047796A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
WO2011161216A1 (en) 2010-06-25 2011-12-29 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
CA2812608C (en) 2010-10-06 2020-07-14 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
CN103282351A (zh) 2010-10-29 2013-09-04 拜耳知识产权有限责任公司 取代的苯氧基吡啶
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
EP2655601A4 (en) 2010-12-22 2014-09-10 Fate Therapeutics Inc CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
EP2655375B1 (fr) 2010-12-23 2014-12-03 Sanofi Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
AU2012236164A1 (en) 2011-04-01 2013-11-21 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
JP6239497B2 (ja) 2011-04-01 2017-11-29 ジェネンテック， インコーポレイテッド Ａｋｔ阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
EP2714039A1 (en) * 2011-05-23 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
ES2597052T3 (es) 2011-05-25 2017-01-13 Université Paris Descartes Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
JP6238459B2 (ja) * 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
KR20140072028A (ko) 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
CA2845571A1 (en) * 2011-09-01 2013-03-07 Novartis Ag Use of organic compound for the treatment of noonan syndrome
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
JP2014532712A (ja) 2011-11-02 2014-12-08 シンタ ファーマシューティカルズ コーポレーション トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法
AU2012339679A1 (en) 2011-11-14 2014-06-12 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with BRAF inhibitors
AU2012340766B2 (en) 2011-11-23 2018-05-10 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
JP6158833B2 (ja) 2012-01-09 2017-07-05 アローヘッド ファーマシューティカルズ インコーポレイテッド ベータ−カテニン関連疾患を処置するための有機組成物
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
JP2015512388A (ja) * 2012-03-20 2015-04-27 ノヴァルティス・ファーマ・アーゲー 併用療法
EP2836873B1 (en) 2012-04-09 2020-03-11 Switch Materials, Inc. Switching materials, and compositions and methods for making same
US9588358B2 (en) 2012-05-29 2017-03-07 Switch Materials, Inc. Optical filter comprising a variable transmittance layer
AU2013269809B2 (en) 2012-05-31 2017-12-21 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP2884979B1 (en) 2012-08-17 2019-06-26 F.Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
MD20150043A2 (ro) 2012-10-02 2015-08-31 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
SMT202400044T1 (it) * 2012-10-19 2024-03-13 Array Biopharma Inc Formulazione comprendente un inibitore di mek
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
NZ708802A (en) 2012-11-29 2019-09-27 Novartis Ag Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
EP2752191A1 (en) 2013-01-07 2014-07-09 Sanofi Compositions and methods using hdm2 antagonist and mek inhibitor
JP2016508726A (ja) 2013-02-22 2016-03-24 セルラー ダイナミクス インターナショナル， インコーポレイテッド 組み合わせた遺伝的および化学的操作によるフォワードプログラミングを介した肝細胞の産生
JP6465790B2 (ja) 2013-02-27 2019-02-06 第一三共株式会社 Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
PE20151667A1 (es) 2013-02-27 2015-11-27 Epitherapeutics Aps Inhibidores de histona desmetilasas
PL2970205T3 (pl) 2013-03-14 2019-10-31 Tolero Pharmaceuticals Inc Inhibitory jak2 i alk2 oraz sposoby ich zastosowania
AU2014233805B2 (en) * 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
EA030730B1 (ru) 2013-12-19 2018-09-28 Идорсиа Фармасьютиклз Лтд Антибактериальные производные 1h-индазола и 1h-индола
EP3094736A4 (en) 2014-01-14 2017-10-25 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
CN104788365B (zh) * 2014-01-16 2018-08-10 上海艾力斯医药科技有限公司 异烟酰胺衍生物、其制备方法及应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
US11268069B2 (en) 2014-03-04 2022-03-08 Fate Therapeutics, Inc. Reprogramming methods and cell culture platforms
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015153498A1 (en) 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
WO2015164228A1 (en) 2014-04-21 2015-10-29 Cellular Dynamics International, Inc. Hepatocyte production via forward programming by combined genetic and chemical engineering
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
ES2742500T3 (es) 2014-07-15 2020-02-14 Federal Express Corp Composiciones para tratamiento del cáncer usando antagonistas de unión al eje de pd-1 e inhibidores de MEK
SG11201701182VA (en) 2014-08-27 2017-03-30 Gilead Sciences Inc Compounds and methods for inhibiting histone demethylases
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SI3237418T1 (sl) 2014-12-23 2019-06-28 Novartis Ag Spojine triazolopirimidina in njihove uporabe
JP6800859B2 (ja) 2015-01-26 2020-12-16 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
EP3274344B1 (en) 2015-03-25 2019-04-24 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN108348520A (zh) 2015-08-28 2018-07-31 诺华股份有限公司 Mdm2抑制剂和其组合
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
US11441126B2 (en) 2015-10-16 2022-09-13 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
EP4046655A1 (en) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN108368520B (zh) 2015-11-04 2023-01-17 菲特治疗公司 多能细胞的基因组工程改造
JP7534070B2 (ja) 2015-11-04 2024-08-14 フェイト セラピューティクス，インコーポレイテッド 造血細胞分化を誘導するための方法および組成物
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN116376826A (zh) 2016-01-20 2023-07-04 菲特治疗公司 用来在过继性免疫疗法中进行免疫细胞调节的组合物和方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
AU2017226389B2 (en) 2016-03-04 2023-02-02 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
JP6805336B2 (ja) 2016-06-03 2020-12-23 アレイ バイオファーマ、インコーポレイテッド 薬学的組み合わせ
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
RU2754856C2 (ru) 2016-06-20 2021-09-08 Новартис Аг Кристаллические формы соединения триазолопиримидина
ES2798424T3 (es) 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018065924A1 (en) * 2016-10-04 2018-04-12 Sun Pharmaceutical Industries Limited Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN108084078B (zh) * 2016-11-24 2021-07-30 中山大学 一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
EP3372624A1 (en) 2017-03-06 2018-09-12 Henkel AG & Co. KGaA One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN109438362B (zh) * 2017-11-14 2020-07-21 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
FI3769765T3 (fi) 2018-03-19 2024-05-15 Taiho Pharmaceutical Co Ltd Natriumalkyylisulfaattia sisältävä farmaseuttinen koostumus
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
BR112020023872A2 (pt) 2018-05-24 2021-02-17 Janssen Biotech, Inc. agentes de ligação de psma e seus usos
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
CN112584875A (zh) 2018-07-25 2021-03-30 先进加速器应用公司 稳定的、浓缩的放射性核素络合物溶液
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
RS64238B1 (sr) 2018-08-17 2023-06-30 Novartis Ag Jedinjenja i sastavi uree kao inhibitori smarca2/brm-atpaze
WO2020064693A1 (en) 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
US12378240B2 (en) 2018-11-20 2025-08-05 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
MA54741A (fr) 2018-11-20 2021-11-24 Nflection Therapeutics Inc Composés thiényl-aniline destinés au traitement d'affections de la peau
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
WO2020128972A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
AU2020222346B2 (en) 2019-02-15 2021-12-09 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
ES3032659T3 (en) 2019-02-15 2025-07-23 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
KR20220002899A (ko) 2019-04-19 2022-01-07 얀센 바이오테크 인코포레이티드 항-psma/cd3 항체로 전립선암을 치료하는 방법
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
IL291499B2 (en) 2019-09-26 2025-08-01 Novartis Ag Aza-quinoline compounds and uses thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
BR112022011902A2 (pt) 2019-12-20 2022-09-06 Novartis Ag Terapias de combinação
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. PROTEOLYSIS REGULATOR AND METHOD OF USE
JP7805285B2 (ja) 2020-04-10 2026-01-23 大鵬薬品工業株式会社 ３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
WO2021250521A1 (en) 2020-06-09 2021-12-16 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
CN112759552A (zh) * 2020-12-31 2021-05-07 武汉九州钰民医药科技有限公司 司美替尼的合成方法
US12141240B2 (en) 2021-01-20 2024-11-12 Rutgers, The State University Of New Jersey Method of calibration using master calibration function
EP4281069A4 (en) * 2021-01-21 2025-09-17 Nflection Therapeutics Inc PROCESSES FOR THE PREPARATION OF PYRROLOPYRIDINE-ANILINE COMPOUNDS
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
CN117794929A (zh) 2021-02-02 2024-03-29 法国施维雅药厂 选择性bcl-xl protac化合物及使用方法
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations
EP4322953A4 (en) * 2021-04-15 2025-01-22 Ideaya Biosciences, Inc. COMBINATION THERAPY WITH A PKC INHIBITOR AND A MEK INHIBITOR
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
MX2023014565A (es) 2021-06-09 2024-02-08 Chugai Pharmaceutical Co Ltd Tratamiento conjunto para tratamiento contra el cancer.
CN115490640B (zh) * 2021-06-17 2024-11-26 深圳市塔吉瑞生物医药有限公司 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
WO2023078881A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
AU2023273734A1 (en) 2022-05-20 2024-12-12 Les Laboratoires Servier Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250340518A1 (en) * 2022-06-06 2025-11-06 Glenmark Life Sciences Limited Process for preparation of selumetinib and salts thereof
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
WO2024209717A1 (ja) 2023-04-06 2024-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
TW202540185A (zh) 2023-11-22 2025-10-16 法商施維雅藥廠 抗cd74抗體藥物結合物及其使用方法
FR3159741A1 (fr) 2024-03-04 2025-09-05 Pierre Fabre Medicament Formulation topique comprenant du binimetinib
TW202539634A (zh) 2024-04-10 2025-10-16 瑞士商諾華公司 Ｐａｎｒａｓ抑制劑及其使用方法
PL451049A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451048A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451046A1 (pl) * 2025-01-27 2025-06-09 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL451050A1 (pl) * 2025-01-27 2025-08-04 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa
PL248506B1 (pl) * 2025-01-27 2025-12-22 Lubelska Polt Kompozytowa konstrukcja przekładkowa
PL451047A1 (pl) * 2025-01-27 2025-08-18 Politechnika Lubelska Kompozytowa konstrukcja przekładkowa

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55501033A (OSRAM) 1978-11-20 1980-11-27
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
US5218356A (en) * 1991-05-31 1993-06-08 Guenther Knapp Wireless indoor data relay system
US5216003A (en) 1992-01-02 1993-06-01 G. D. Searle & Co. Diacid-containing benzimidazole compounds for treatment of neurotoxic injury
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5750545A (en) 1993-07-23 1998-05-12 The Green Cross Corporation Triazole derivative and pharmaceutical use thereof
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5520187A (en) 1994-11-25 1996-05-28 General Electric Company Ultrasonic probe with programmable multiplexer for imaging systems with different channel counts
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
GB9600344D0 (en) 1996-01-09 1996-03-13 Lilly Co Eli Benzimidzolyl neuropeptide y receptor antagonists
CN1225639A (zh) 1996-07-18 1999-08-11 美国辉瑞有限公司 基于次膦酸酯的基质金属蛋白酶抑制剂
SK21499A3 (en) 1996-08-23 2000-05-16 Pfizer Arylsulfonylamino hydroxamic acid derivatives
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
SK283963B6 (sk) 1997-02-03 2004-06-08 Pfizer Products Inc. Deriváty arylsulfonylaminohydroxamovej kyseliny, farmaceutický prostriedok, spôsob inhibície matričných metaloproteináz alebo produkcie faktora nekrózy nádorov
WO1998034915A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (ja) 1997-02-11 2005-10-26 ファイザー・インク アリールスルホニルヒドロキサム酸誘導体
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
BR9810366A (pt) 1997-07-01 2000-08-29 Warner Lambert Co Derivados de ácido 4-bromo ou 4-iodo fenilamino benzidroxîmico e seu uso como inibidores de mek
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
DE69836378T2 (de) 1997-07-01 2007-10-11 Warner-Lambert Co. Llc Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AU2483000A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Treatment of asthma with mek inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
EE200100373A (et) * 1999-01-13 2002-10-15 Warner-Lambert Company Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
CA2349467A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
BR9916896A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Diaril aminas substituìdas com 1-heterociclo
BR9916885A (pt) * 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
JP2000204077A (ja) 1999-01-13 2000-07-25 Warner Lambert Co ジアリ―ルアミン
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
TR200200204T2 (tr) 1999-07-16 2002-11-21 Warner-Lambert Company MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
CA2377092A1 (en) * 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DK1202724T3 (da) 1999-07-16 2004-01-26 Warner Lambert Co Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
US7030119B1 (en) * 1999-07-16 2006-04-18 Warner-Lambert Company Method for treating chronic pain using MEK inhibitors
EP1202726A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
EP1214330A1 (en) 1999-09-21 2002-06-19 LION Bioscience AG Benzimidazole derivatives and combinatorial libraries thereof
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
US7001905B2 (en) * 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
CN1458921A (zh) 2000-08-25 2003-11-26 沃尼尔·朗伯有限责任公司 N－芳基邻氨基苯甲酸和它们的衍生物的制备方法
AU2002210714A1 (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
AU2002221239A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
JP4544820B2 (ja) 2001-03-09 2010-09-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 複素環化合物
US20040039208A1 (en) 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
EP1427408A4 (en) 2001-09-17 2005-10-26 Bristol Myers Squibb Co CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM)
WO2003054180A1 (en) 2001-12-21 2003-07-03 Warner-Lambert Company Llc Modified mek1 and mek2, crystal of a peptide: ligand: cofactor complex containing such modified mek1 or mek2, and methods of use thereof
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US20030216460A1 (en) * 2002-03-13 2003-11-20 Wallace Eli M. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL230179B1 (pl) 2002-03-13 2018-09-28 Array Biopharma Inc N3 Alkilowane pochodne benzoimidazolu, kompozycja je zawierająca oraz ich zastosowanie do wytwarzania leku do leczenia zaburzeń hiperproliferacyjnych
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
CN1694704A (zh) 2002-09-06 2005-11-09 詹森药业有限公司 （1h－苯并咪唑－2－基）－（哌嗪基）－甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
DE102005032379A1 (de) 2005-07-08 2007-01-11 Conti Temic Microelectronic Gmbh Zugangskontrollsystem für ein Kraftfahrzeug
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US9867825B2 (en) 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib

Also Published As

Publication number Publication date
US20100267710A1 (en) 2010-10-21
KR100984613B1 (ko) 2010-09-30
CN1652776A (zh) 2005-08-10
SG2013013339A (en) 2014-12-30
US20100267793A1 (en) 2010-10-21
PL401637A1 (pl) 2013-05-27
DE60330227D1 (de) 2010-01-07
KR20100040759A (ko) 2010-04-20
NZ535158A (en) 2007-06-29
DK3000810T3 (en) 2017-10-16
HUE025767T2 (en) 2016-05-30
AU2009222613B2 (en) 2011-06-16
IS2748B (is) 2011-08-15
US20120277277A1 (en) 2012-11-01
WO2003077914A1 (en) 2003-09-25
KR20100040760A (ko) 2010-04-20
US8193231B2 (en) 2012-06-05
AR090144A2 (es) 2014-10-22
JP4093966B2 (ja) 2008-06-04
US8193229B2 (en) 2012-06-05
JP5102642B2 (ja) 2012-12-19
JP5498546B2 (ja) 2014-05-21
CL2012002380A1 (es) 2012-11-05
CN101633644A (zh) 2010-01-27
AR038971A1 (es) 2005-02-02
ES2549159T3 (es) 2015-10-23
HK1141976A1 (en) 2010-11-26
CN101633645B (zh) 2011-06-22
CN101633645A (zh) 2010-01-27
HK1153139A1 (en) 2012-03-23
EP2130537B1 (en) 2012-11-14
BR122018007328B1 (pt) 2020-03-03
US20100260714A1 (en) 2010-10-14
TW200407129A (en) 2004-05-16
US8178693B2 (en) 2012-05-15
PL233177B1 (pl) 2019-09-30
SI2275102T1 (sl) 2015-12-31
PL401635A1 (pl) 2013-05-27
PL233493B1 (pl) 2019-10-31
FR19C1014I1 (fr) 2019-04-19
EP2130536A1 (en) 2009-12-09
LTC1482932I2 (lt) 2020-04-27
DOP2013000023A (es) 2013-06-30
SI3000810T1 (sl) 2017-10-30
PT2130537E (pt) 2012-12-20
US8513293B2 (en) 2013-08-20
AR090143A2 (es) 2014-10-22
DK2275102T3 (en) 2015-11-02
AU2003218157A1 (en) 2003-09-29
TWI350285B (en) 2011-10-11
US8193230B2 (en) 2012-06-05
DOP2011000110A (es) 2011-11-30
EP2275102B1 (en) 2015-07-29
LUC00100I2 (OSRAM) 2020-01-23
US20080177082A1 (en) 2008-07-24
IS8959A (is) 2011-06-16
TW201031641A (en) 2010-09-01
EP2130537A1 (en) 2009-12-09
PA8569301A1 (es) 2004-10-08
BE2019C510I2 (OSRAM) 2022-05-19
EP1482932B1 (en) 2009-11-25
IL163995A (en) 2010-11-30
RU2307831C9 (ru) 2008-06-10
CY2019012I2 (el) 2020-05-29
ZA200407220B (en) 2007-05-30
PT3000810T (pt) 2017-10-25
EP1482932A4 (en) 2006-04-05
IL204420A0 (en) 2011-07-31
DOP2011000109A (es) 2011-11-30
JP2008019277A (ja) 2008-01-31
ES2335276T3 (es) 2010-03-24
PL230179B1 (pl) 2018-09-28
ES2407849T3 (es) 2013-06-14
SG148857A1 (en) 2009-01-29
KR20040094786A (ko) 2004-11-10
US20030232869A1 (en) 2003-12-18
IL204419A (en) 2012-12-31
NL300974I2 (nl) 2022-04-06
AU2009222613A1 (en) 2009-10-29
MXPA04008893A (es) 2005-06-20
CN100519539C (zh) 2009-07-29
CN101486682B (zh) 2013-08-14
CL2012002381A1 (es) 2012-11-05
IL163995A0 (en) 2005-12-18
LTPA2019007I1 (lt) 2019-03-25
US7973170B2 (en) 2011-07-05
HK1070823A1 (en) 2005-06-30
LUC00100I1 (OSRAM) 2019-02-13
CN101486682A (zh) 2009-07-22
RU2004127926A (ru) 2005-06-27
CN101633644B (zh) 2012-05-09
US20080171778A1 (en) 2008-07-17
DOP2003000613A (es) 2003-09-30
IS2998B (is) 2018-06-15
PT2275102E (pt) 2015-10-27
US7777050B2 (en) 2010-08-17
RU2307831C2 (ru) 2007-10-10
EP3000810A1 (en) 2016-03-30
EP2130536B1 (en) 2013-05-08
IL204419A0 (en) 2011-07-31
IS8960A (is) 2011-06-16
PL401638A1 (pl) 2013-05-27
IS2990B (is) 2017-12-15
SG194238A1 (en) 2013-11-29
US7425637B2 (en) 2008-09-16
PT1482932E (pt) 2010-01-12
EP1482932A1 (en) 2004-12-08
US20100261718A1 (en) 2010-10-14
EP2275102A1 (en) 2011-01-19
BR122018007328B8 (pt) 2021-05-25
FR19C1014I2 (fr) 2020-03-13
ES2635666T3 (es) 2017-10-04
IS8961A (is) 2011-06-16
TWI343377B (en) 2011-06-11
JP2005530709A (ja) 2005-10-13
ATE449605T1 (de) 2009-12-15
US20110158971A1 (en) 2011-06-30
UA77765C2 (en) 2007-01-15
PL401636A1 (pl) 2013-05-27
US20100261717A1 (en) 2010-10-14
US20050143438A1 (en) 2005-06-30
KR100984595B1 (ko) 2010-09-30
IS2999B (is) 2018-06-15
EP3000810B1 (en) 2017-07-19
IS7442A (is) 2004-09-09
US8003805B2 (en) 2011-08-23
ES2394347T3 (es) 2013-01-30
DK2130537T3 (da) 2013-02-18
KR100984573B1 (ko) 2010-09-30
TW201031642A (en) 2010-09-01
TWI338685B (en) 2011-03-11
SI1482932T1 (sl) 2010-02-26
CY2019012I1 (el) 2020-05-29
AU2003218157B2 (en) 2009-07-09
PL377628A1 (pl) 2006-02-06
CY1119136T1 (el) 2018-02-14
US7576114B2 (en) 2009-08-18
HUS1900011I1 (hu) 2019-04-29
CA2478374A1 (en) 2003-09-25
AU2003218157C1 (en) 2011-11-24
JP2008163034A (ja) 2008-07-17
IL204420A (en) 2012-12-31
DK1482932T3 (da) 2010-02-01
JP2012224649A (ja) 2012-11-15
SI2130537T1 (sl) 2013-01-31
CY1109727T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
CA2478374C (en) N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) N3 alkylated benzimidazole derivatives as MEK inhibitors
HK1070823B (en) N3 alkylated benzimidazole derivatives as mek inhibitors
HK1141976B (en) N3 alkylated benzimidazole derivatives as mek inhibitors
HK1153139B (en) N3 alkylated benzimidazole derivatives as mek inhibitors

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230313